News & Views | Published:

Gene therapy

A path to efficient gene editing

Signaling by the tumor-suppressor protein p53 antagonizes CRISPR–Cas9 gene editing of human pluripotent stem cells and immortalized human retinal pigment epithelial cells.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Urnov, F. D. CRISPR J. 1, 34–46 (2018).

  2. 2.

    Doudna, J. A. & Charpentier, E. Science 346, 1258096–1258096 (2014).

  3. 3.

    Hockemeyer, D. & Jaenisch, R. Cell Stem Cell 18, 573–586 (2016).

  4. 4.

    Ihry, R. J. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0050-6 (2018).

  5. 5.

    Haapaniemi, E. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0049-z (2018).

  6. 6.

    Meyers, R. M. et al. Nat. Genet. 49, 1779–1784 (2017).

  7. 7.

    Tebas, P. et al. N. Engl. J. Med. 370, 901–910 (2014).

  8. 8.

    Qasim, W. et al. Sci. Transl. Med. 9, eaaj2013 (2017).

  9. 9.

    Urnov, F. D. Curr. Opin. Genet. Dev. 52, 48–56 (2018).

  10. 10.

    Schwartz, S. D. et al. Lancet 385, 509–516 (2015).

  11. 11.

    da Cruz, L. et al. Nat. Biotechnol. 36, 328–337 (2018).

  12. 12.

    Dunbar, C. E. et al. Science 359, eaan4672 (2018).

Download references

Author information

Competing interests

The author declares no competing interests.

Correspondence to Fyodor D. Urnov.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading

Fig. 1: Induction of p53 contributes to inefficient gene editing in hPSCs.

Marina Spence/Springer Nature